These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24790218)

  • 21. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas.
    Ambrosini V; Campana D; Polverari G; Peterle C; Diodato S; Ricci C; Allegri V; Casadei R; Tomassetti P; Fanti S
    J Nucl Med; 2015 Dec; 56(12):1843-8. PubMed ID: 26405169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodistribution and pharmacokinetics of [
    García-Varela L; Codesido J; Perez-Pedrosa A; Muñoz-González M; Ramos-Docampo E; Rey-Bretal D; García-Otero X; Gómez-Lado N; Turrero A; Beiroa D; Rodríguez-Perez AI; Vidal A; Fernández-Ferreiro A; Pubul V; Aguiar P
    Int J Pharm; 2024 Mar; 652():123795. PubMed ID: 38224761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
    Lee DY; Kim YI
    Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET.
    Chang AJ; Sohn R; Lu ZH; Arbeit JM; Lapi SE
    PLoS One; 2013; 8(3):e58949. PubMed ID: 23516584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma.
    Veldhuijzen van Zanten SEM; Sewing ACP; van Lingen A; Hoekstra OS; Wesseling P; Meel MH; van Vuurden DG; Kaspers GJL; Hulleman E; Bugiani M
    J Nucl Med; 2018 Apr; 59(4):612-615. PubMed ID: 28818988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interobserver reproducibility of tumor uptake quantification with
    Jauw YWS; Bensch F; Brouwers AH; Hoekstra OS; Zijlstra JM; Pieplenbosch S; Schröder CP; Zweegman S; van Dongen GAMS; Menke-van der Houven van Oordt CW; de Vries EGE; de Vet HCW; Boellaard R; Huisman MC
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1840-1849. PubMed ID: 31209514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors.
    Campana D; Ambrosini V; Pezzilli R; Fanti S; Labate AM; Santini D; Ceccarelli C; Nori F; Franchi R; Corinaldesi R; Tomassetti P
    J Nucl Med; 2010 Mar; 51(3):353-9. PubMed ID: 20150249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic neuroendocrine neoplasms.
    Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
    Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
    Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
    Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
    Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
    Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
    J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.